Neuphoria Therapeutics Inc (NEUP) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Neuphoria Therapeutics Inc (NEUP), noting its current score of 1.18, ranking 321 out of 384 in the Biotechnology & Medical Research industry. The company's beta of 0.73 indicates it tends to underperform during rising markets but experiences …